Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.
about
Clinical experience with plerixafor as a mobilization regimen for autologous peripheral blood stem cell transplantation in patients with refractory germ cell tumors.Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experienceImportance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept.Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients.New strategies for stem cell mobilization.G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation.Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide.Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin's Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization.Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.Outcome, toxicity profile and cost analysis of autologous stem cell mobilization.A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs.Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.
P2860
Q34265754-49D75D40-53EB-4892-9A78-ECD94E0C65B7Q34762492-606B93D9-3AAA-493E-A6C2-D3DB12F40E62Q37827058-41E97290-CD41-44CF-A205-B52B50557E50Q37921284-23BFCBE5-CE3A-4916-BE0A-FD7F5F8B186AQ37943423-E2D28002-7DD3-4A40-9653-A8CD287E130EQ38160461-DCC7AE3F-9210-4BF2-85AF-95372F727C19Q38200909-0B312BF4-AB0A-4751-95B5-D36020D95FE5Q38880504-8EE9C9BE-BE08-41B4-ACE7-E66AE1F33E1EQ39177577-DCA57AC2-AEDA-4F8D-8FE5-2C217BCFFA97Q39724267-FBA6D0C2-9329-4FF5-916D-8FFB0C3799AAQ41104670-857100D4-D532-47AA-8E0F-02EAB69EB87EQ41267193-078491D4-7ED2-43B5-B448-CC2ED6AB514FQ42184785-DC26A5B2-7138-41A0-9E88-BDFAD155E93AQ44736591-D84A9BFC-C735-46BB-8EB3-5AC0EB11F38EQ45735258-D310E869-5D0D-499A-8958-149826E2D9B9Q45752095-5F594D12-B743-4500-9C5E-2F4362DCE871Q45892382-BE573C08-F216-4D62-8FC9-15046660254DQ47914097-1B0BCD20-0354-4E63-82C5-883C4CBEAFC3Q50150301-A0C04D04-1A80-4ECD-AC18-BEE0DB3BB658Q51057684-63202224-7A31-450E-A5D5-AAE451C75801Q51385709-40180352-49F5-4598-A7B9-7EB8BEBF075DQ51405815-DC6A2A13-0276-4DFD-B927-A3F0E1FAD4B0Q51680781-B9997C56-9B31-4254-9C24-8D5262AF1DA1Q51705517-D6902358-9507-433D-84F2-81B13E4F2EB7Q53291951-D2933970-21BE-4917-ABB2-54C4D9976B44Q53508311-81CF578B-3346-483B-BD2D-4532693D9F84Q54582789-9B695DA0-21BD-45C1-9A3D-AED68405D3AB
P2860
Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Safety and efficacy assessment ...... nt of tumor cell mobilization.
@en
Safety and efficacy assessment ...... nt of tumor cell mobilization.
@nl
type
label
Safety and efficacy assessment ...... nt of tumor cell mobilization.
@en
Safety and efficacy assessment ...... nt of tumor cell mobilization.
@nl
prefLabel
Safety and efficacy assessment ...... nt of tumor cell mobilization.
@en
Safety and efficacy assessment ...... nt of tumor cell mobilization.
@nl
P2093
P2860
P356
P1476
Safety and efficacy assessment ...... nt of tumor cell mobilization.
@en
P2093
G Calandra
M H Cottler-Fox
P2860
P2888
P356
10.1038/BMT.2009.130
P407
P577
2009-06-22T00:00:00Z
P5875
P6179
1038025354